Benefits and harms of detecting clinically occult breast cancer

Journal of the National Cancer Institute

Volumn 104, Issue 20, 2012, Pages 1542-1547

  Amir, Eitan ^a   Bedard, Philippe L ^a   Ocaña, Alberto ^a,b   Seruga, Bostjan ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; LYMPHEDEMA; MAMMOGRAPHY; MOTOR NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGE FACTORS; AGED; AXILLA; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; STRESS, PSYCHOLOGICAL; UNNECESSARY PROCEDURES;

EID: 84867711680     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs394     Document Type: Review

References (55)

1. National Cancer Institute. Surveillance Epidemiology and End Results. Age-Adjusted U.S. Mortality Rates for Breast Cancer 1975-2009. http://seer.cancer.gov/faststats. Accessed August 21, 2012.
2. Welch HG. Screening mammography-a long run for a short slide? N Engl J Med. 2010;363(13):1276-1278.
3. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-742.
4. Canadian Task Force on Preventive Health Care, Tonelli M, Gorber SC, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ. 2011;183(17):1991-2001.
5. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009;Oct(4):CD001877.
6. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102(10):680-691.
7. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003;361(9367):1411-1417.
8. Duffy SW, Tabar L, Chen HH, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95(3):458-469.
9. Autier P, Boniol M, Middleton R, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol. 2011;22(8):1726-1735.
10. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363(13):1203-1210.
11. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011;343:d4411.
12. Groenendijk RP, Bult P, Tewarie L, et al. Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer. 2000;82(2):381-384.
13. Esserman LJ, van 't Veer LJ, Perou C, et al. Biology of breast cancers that are screen detected vs. locally advanced or young age should inform how we approach early detection and prevention [abstract 6034]. Cancer Res. 2009;69(2 Suppl):Abstract 6034.
14. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167-173.
15. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138(3): 168-175.
16. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: understanding the trade-offs. JAMA. 2010;303(2):164-165.
17. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089-1096.
18. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481-492.
19. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
20. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127(11):1023-1028.
21. Zahl PH, Gotzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol. 2011;12(12):1118-1124.
22. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ. 2006;332(7543):689-692.
23. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156(7):491-499.
24. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587.
25. Kopans DB, Smith RA, Duffy SW. Mammographic screening and "overdiagnosis." Radiology 2011;260(3):616-620.
26. Jorgensen KJ, Keen JD, Gotzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 2011;260(3):621-627.
27. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-726.
28. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.
29. Kopans DB. The 2009 US Preventive Services Task Force (USPSTF) guidelines are not supported by science: the scientific support for mammography screening. Radiol Clin North Am. 2010;48(5):843-857.
30. Hendrick RE, Helvie MA. United States Preventive Services Task Force screening mammography recommendations: science ignored. Am J Roentgenol. 2011;196(2):W112-W116.
31. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol. 2008;26(19):3248-3258.
32. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin. 2009;59(5):290-302.
33. Mann RM, Hoogeveen YL, Blickman JG, Boetes C. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2008;107(1):1-14.
34. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
35. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010;375(9714):563-571.
36. Peters NH, van ES, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MO. Eur J Cancer. 2011;47(6):879-886.
37. Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol. 2012;19(2):536-540.
38. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol. 2008;26(3):386-391.
39. Große R, Kantelhardt EJ, Steer S, et al. Does routine use of preoperative magnetic resonance imaging (MRI) in breast cancer influence the uutcome? [abstract P2-08-13]. Cancer Res. 2011;15(Suppl):Abstract P2-08-13.
40. Wedegartner U, Bick U, Wortler K, Rummeny E, Bongartz G. Differentiation between benign and malignant findings on MR-mammography: usefulness of morphological criteria. Eur Radiol. 2001;11(9):1645-1650.
41. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158-2164.
42. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011;378(9805):1804-1811.
43. McCready DR, Yong WS, Ng AKT, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 2004;96(11):873-875.
44. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
45. Galimberti V, Cole BF, Zurrida S, et al. Update of international breast cancer study group trial 23-01 to compare axillary dissection versus no axillary dissection in patients with clinically node negative breast cancer and micrometastases in the sentinel node [abstract S3-1]. Cancer Res. 2011;15(Suppl):Abstract S3-1.
46. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-432.
47. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599-609.
48. Houssami N, Abraham LA, Miglioretti DL, et al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA. 2011;305(8):790-789.
49. Ghezzi P, Magnanini S, Rinaldini M, et al. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994;271(20):1587-1592.
50. Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-Year update of a randomized trial. JAMA. 1999;281(17):1586.
51. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091-5097.
52. Aebi S, Davidson T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v9-14.
53. Panageas KS, Sima CS, Liberman L, Schrag D. Use of high technology imaging for surveillance of early stage breast cancer. Breast Cancer Res Treat. 2012;131(2):663-670.
54. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol. 2011;29(19):2619-2627.
55. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2628-2634.